EudraCTPhaseTherapeutic AreaPrincipal InvestigatorURL
2015-001564-19IIOncologyHerlander MarquesMore info
CLBH5892222: A multicenter, randomized, open-label Phase 2 study evaluating the safety and efficacy of three different doses of oral panobinostat in combination with subcutaneous bortezomib and oral dexamethasone in patients with relapsed multiple myeloma who have been previously exposed to immunomodulatory agents

2016-002625-11IIIOncologyJúlia AmorimMore info
SAUL: an open label, single arm, multicentre, safety study of atezolizumab in locally advanced or mestastatic urothelial carcinoma ou non-urothelial urinary tract carcinoma

2016-003467-19IIIOncologyCatarina PortelaMore info
COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribocicib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

2017-000657-39IIIAnesthesiaBelinda OliveiraMore info
NAXOS: Randomized, Double-Blind, Placebo controled, paralel group design, multi center, phase III study to investigate the eficacy, safety and tolerability of Naloxone HCLPR Tablets in Patients With opioid induced constipation and chronic non cancer pain

IIIInfections DisordersAlexandre CarvalhoMore info
CLOVER (B5091007): Phase III, placebo-controlled, endpoint driven vaccine efficacy study for prevention of Clostridium difficile infection in subjects 50 years or older

2016-002154-20IIICardiologyPedro AzevedoMore info
PARADISE: Prospective ARNI versus ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction

2016-000434-21IIINeurologyJoao CerqueiraMore info
PLENO: Estudo aberto, randomizado, de 2 grupos com comparador ativo para avaliar a segurança e a tolerabilidade em doentes portugueses com esclerose multipla surto-remissao em transição de terapêutica de rotina com interferão subcutâneo para peginterferão Beta 1a (PLEGRIDY)

2015-005419-33IIINeurologyJoao CerqueiraMore info
ASCLEPIOS: A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatunumab versus teriflunomide in patients with relapsing multiple sclerosis

2015-003623-65IIIDermatologyCeleste BritoMore info
BI 1311.30 versus adalimumab in a randomized, double-blind, parallel group trial in moderate to severe plaque psoriasis to assess safety and efficacy after 16 weeks of treatment and after inadequate adalimumab treatment response

2016-003046-87IIIDermatologyCeleste BritoMore info
M15-997 (LIMITLESS): psoriase (extensao)

2015-001106-33IIIRheumatologyAna RoxoMore info
CAIN457H2315: espondilartrite

2015-003333-95IIIRheumatologyAna RoxoMore info
M14-465: A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)

IIaOphthalmologyNuno GomesMore info
BI 1320.22: A randomized, double-blind, placebo-controlled exploratory study to evaluate pharmacodynamics, safety and tolerability of orally administered BI 1026706 for 12 weeks in patients with mild visual impairment due to center-involved diabetic macular edema (DME)

2014-005324-10IIIOncologyHerlander MarquesMore info
CT-P10 3.4: A Phase 3, Randomises, Parallel-Group, Active-Controlled, Double-Blind Study to Compare the Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumor Burden Follicular Lymphoma

Disease / Condition - RegistryPsychiatryPedro MorgadoMore info
ANG-15: Nutrition interventional study, to evaluate the benefit of a combination of omega-3 fatty acids, magnesium, folic acid, vitamin B12 and vitamin E, in adult patients suffering from major depression

Exposure or Drug-Registry UrologyEstêvão LimaMore info
EUROPA: A non-interventional study assessing the impact on quality of life, of patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BHP) treated with Vesomni/ Urizia/ Volutsa in routine clinical practice. A post authorization study (PAS).

2015-003529-33IIaOphthalmologyNuno GomesMore info
BI 1320.22: A randomized, double-masked, placebo-controlled exploratory study to evaluate pharmacodynamics, safety and tolerability of orally administered BI 1026706 for 12 weeks in patients with mild visual impairment due to center-involved diabetic macular edema (DME)

2016-000991-49IIIPediatricsAlmerinda Barroso PereiraMore info
DU 176b-D-U312: A phase 3, open-label randomized, multi-center, controlled trial to evaluate the pharmacokinetics and pharmacodynamics of edoxaban and to compare the efficacy and safety of edoxaban with standard of care anticoagulant therapy in pediatric patients from birth to less than 18 years of age with confimed venous thromboembolism (VTE)

Exposure or Drug-Registry NeurologyJoão CerqueiraMore info
ESTEEM: A Multicenter, Global,Observational Study to Collect Information on Safety and to Document the Drug Utilization of BG00012 When Used in Routine Medical Practive in the Treatment of Relapsing Multiple Sclerosis

2014-001458-40IIIbOncologyCatarina PortelaMore info
METAPHER: A Multicenter, Open-label, Single-Arm Safety Study of Herceptin SC in Combinaton With Perjeta and Docetaxel in Treatment of Patients With HER2-Positive Advanced Breast Cancer (Metastatic or Locally Recurrent)

2012-004360-22IIPediatricsJorge Correia-PintoMore info
RELYON: An open-label trial, enrolling subjects aged 6 years to less than 18 years suffering from pain requiring prolonged release opioid treatment, to evaluate the safety and efficacy of tapentadol PR versus morphine PR, followed by an open-label extension

2013-000046-19IIICardiologyAntonio GasparMore info
COMMANDER: A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure

2015-002687-16IIISurgeryFernanda NogueiraMore info
REVIVE 2: A Phase 3, Randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to Gram-positive pathogens

2013-004435-72IIIGastroenterologyRaquel GonçalvesMore info
COTTONWOOD: An open-label extension and safety monitoring study of moderate to severe ulcerative colitis patients previously enrolled in Etrolizumab phase III studies

Drug utilization study or Clinical Practice caracterizationPulmonologyJoão CunhaMore info
SPRINT: A Phase IV Real-World Multi-Country Observational Study on Patients' Disease Control and Self-Reported Outcomes During Fixed Dose Combination Dry Powder Inhaler Treatment for Persistent Asthma and COPD (SPRINT)

2015-003471-30IIIUrologyEstêvão LimaMore info
DYSPORT: A phase III, multicentre, randomised, double blind parallel group, placebo controlled study to assess the efficacy and safety of one or more intradetrusor treatments of 600 or 800 units of Dysport for the treatment of urinary incontinence in subjects with neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis

2014-004689-11IIIOncologyHerlander MarquesMore info
MorphoSys 2609-0020: A Phase III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)

2015-003895-65IIICardiologyAntónio GasparMore info
Dal-GenE: A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The Dal-GenE trial

2014-005256-26IIIEndocrinologyMarta AlvesMore info
EASE-3 (BI 1245.72): A Phase III, randomised, double blind, placebo-controlled,parallel group, efficacy, safety and tolerability trial of Empagliflozin, as Adjunctive to insulin over 26 weeks in patients with Type 1 Diabetes Mellitus (EASE-3)

Exposure or Drug-Registry CardiologySergia RochaMore info
RE-SONANCE (BI 1160.247): Non-interventional study describing patients' perception on anticoagulant treatment and treatment convenience when treated with Pradaxa or Vitamin K Antagonist for Stroke Profilaxis in Atrial Fibrillation (Pradaxa pantient convenience trial)

2015-000937-54IIOphthalmologyTiago MonteiroMore info
MC2-03-C1: A Phase II, Multicenter, Randomized, Double-Masked, 4 Parallel Arm, Controlled 6-Month Trial Designed to Evaluate the Safety and Efficacy of PAD Ciclosporin (CsA 0.06% and 0.03%) Ophtalmic Dispersion Administered Once Daily in Combination with Lubricant Therapy and a 3-Month Post-Treatment Safety Follow-Up in Moderate to Severe Dry Eye Patients

2008-000906-35IIIIntensive careAnabela MesquitaMore info
INHALE-2: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients with Gram-Negative Pneumonia

2015-000340-42IIIOncologyCatarina PortelaMore info
SOLAR-1: A phase III randomized double-blind, placebo-controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER-2 negative advanced breast cancer wich progressed on or after aromatase inhibitor treatment

2015-002683-16IIIOncologyDaniela MarquesMore info
TAS-102 (Gastric Cancer): A Randomized, Double-Blind Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments

2011-002605-29IIIEndocrinologyOlinda MarquesMore info
NN2211-3659: Efficacy and safety of liraglutide in combination with metformin versus metformin monotherapy on glycaemic control in children and adolescents with type 2 diabetes

2014-001215-39IIEndocrinologyOlinda MarquesMore info
NN9828-4150: A randomized, double-blind, double-dummy, placebo-controlled, parallel-group multi-centre clinical proof-of-principle trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of NNC0114-0006 and liraglutide on preservation of beta-cell function

2015-000990-11IIIEndocrinologyOlinda MarquesMore info
FIDELIO: A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate

2014-005339-15IIIDermatologyCeleste BritoMore info
OPTIMISE: Long term clear skin maintenance treatment optimization in patients with moderate to severe chronic plaque psoriasis: A randomized, multicenter, open-label with blinded-assessment, comparative, 52 week study to evaluate the efficacy, safety and tolerability of secukinumab 300 mg s.c.

2012-000540-10IIINeurologyJoão CerqueiraMore info
OPTIMUM: Oral Ponesimod versus Teriflunomide In relapsing multiple sclerosis: Multicenter, randomized, double-blind, parallel-group, active-controlled,superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis

Exposure or Drug-Registry NeurologyJoão CerqueiraMore info
REALMS: Estudo observacional, retrospetivo, multicêntrico,nacional, para avaliar a experiência na prática clínica comum do tratamento com fingolimod (Gylenia) em doentes com esclerose múltipla de surto-remissão. Estudo REALMS

2015-000966-72IIINeurologyÁlvaro MachadoMore info
ENGAGE: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease

Exposure or Drug-Registry PediatricsHenedina AntunesMore info
CAPE STUDY: A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of Humira (Adalimumab) in Pediatric Patients with Moderately to Severely Active Crohn's Disease (CD) - CAPE

2015-001368-20IVOphthalmologyLuis MendonçaMore info
ATLANTIC: A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in patients with Polypoidal Choroidal Vasculopathy (ATLANTIC)

2015-000939-33IIIGastroenterologyRaquel GonçalvesMore info
MLN0002-3026: A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab in Subjects With Ulcerative Colitis

2014-002004-24IIbCardiologyAntónio GasparMore info
AUGUSTUS: An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention

2013-003820-36IIIUrologyEstevão LimaMore info
ARAMIS: A multinational, randomised, double-blind, placebo-controlled, phase III efficacy and safety study of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer

2012-002940-26IIIUrologyEstevão LimaMore info
212082PCR3011: A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)

2014-001394-13IIIOncologyHerlander MarquesMore info
C16021: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

2014-001309-42IIIOncologyHerlander MarquesMore info
CINC424B2001X (Polycytemia Vera): An open-label, multi-center, Expanded Treatment Protocol (ETP) of ruxolitinib in patients with Polycythemia Vera (PV) who are Hydroxyurea (HU) resistant or intolerante and for whom no treatment alternatives are available

2014-000268-17IIIOncologyHerlander MarquesMore info
CC-4047-MM-007: A Phase 3, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

2015-001166-26IIbOncologyMarta AlmeidaMore info
M13-813: A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (INTELLANCE 1)

2012-002862-11IIIIntensive careLuis LencastreMore info
ASPECT-NP: A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study To Assess The Safety And Efficacy of Intravenous Ceftolozane/Tazobactam Compared With Meropenem In Adult Patients With Ventilated Nosocomial Pneumonia

2014-003186-24IIIOphthalmologyNuno LopesMore info
ARTEMIS II : The Efficacy and Safety of Bimatoprost SR in Patients with Open-angle Glaucoma or Ocular Hypertension

2013-002076-41IIIOncologyHerlander MarquesMore info
C16019: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant

2014-000132-41IIIOncologyMarta AlmeidaMore info
B3281006: A Phase 3, Randomized, Double-Blind Study of PF-05280586 Versus Rituximab for the First-Line Treatment of Patients with CD-20 Positive, Low Tumor Burden, Follicular Lymphoma

2011-003151-20IIbNeurologyÁlvaro MachadoMore info
EPOCH: A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 with a Long Term Double-Blind Extension in Subjects with Mild to Moderate Alzheimer's Disease.

Drug utilization study or Clinical Practice caracterizationCardiologyJoão CostaMore info
REPARA: Register of patients with Bioresorbable Device in daily clinical practice

Disease / Condition - RegistryUrologyEstevão LimaMore info
212082PCR4001: A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of The Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer

2013-005040-28IINeurologyÁlvaro MachadoMore info
BI 1289.7: A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of oral administrated BI 409306 during a 12-week treatment period compared to donepezil and placebo in patients with cognitive impairment due to Alzheimer's Disease

2010-020337-99IIINeurologyJoão CerqueiraMore info
OPERA I: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1A (REBIF) in Pacients with Relapsing Multiple Sclerosis

2014-002320-27IIINeurologyJoão CerqueiraMore info
SUNBEAM: A Phase 3, Multi-center, Randomized, Double-blind, Double-Dummy, Active-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients

Exposure or Drug-Registry NeurologyJoão CerqueiraMore info
LIBERATE: A Multicenter, Multinational, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra When Used In Routine Medical Practice

2012-003056-36IIINeurologyJoão CerqueiraMore info
CBAF312A2304 (EXPAND): A multicenter, randomized, double-blind, parallel-group, placebo controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis.

2013-003444-24IIINeurologyCarla FerreiraMore info
RESPECT ESUS: Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the Efficacy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral q.d.) in patients with Embolic Stroke of Undetermined Source

2014-002275-28IIIbPulmonologyJoão CunhaMore info
DYNAGITO: A randomized, double-blind,active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared with tiotropium on Chronic Obstructive Pulmunary Disease (COPD) exarcebation in patients with severe to very severe COPD

2013-002513-35IIIbCardiologyJosé MarizMore info
RELAX-AHF-EU: A multicenter, prospective, randomizes, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients

2011-004148-23IVCardiologyJosé MarizMore info
CARMELINA: A multicenter, international, randomized, parallel group, double-blind, placebo-controlled Cardiovascular Safety & Renal Microvascular outcome study with Linagliptin, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk

2013-000951-42IIINephrologyCarlos SoaresMore info
DOLOMITES: A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of FG 4592 in the Treatment of Anemia in Chronic Kidney Disease

2012-004128-39IVOncologyHerlander MarquesMore info
C25006: A Phase 4,Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

2013-002431-15IVOphthalmologyNuno GomesMore info
SALT: A 12-month, phase IV, randomized, open label, multicenter study to compare efficacy of 0.5 mg ranibizumab PRN versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability till month 6 of treatment and explore functional outcomes up to month 12 in patients with neovascular (wet) age-related macular degeneration (AMD)

2010-020454-34IIIOncologyHerlander MarquesMore info
20090482: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zolendronic Acid (Zometa) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma

2013-004282-14IIIGastroenterologyRaquel GonçalvesMore info
GARDENIA: Phase III, Randomized, Multicenter Double-Blind, Double-Dummy Study to Evaluate the Efficacy and Safety of Etrolizumab Compared with Infliximab in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors

2013-001352-34IIIOncologyCatarina PortelaMore info
B3271002: A Phase 3 Randomized, Double-blind Study of PF-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel for the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

2013-005020-42IIIPulmonologyJoão CunhaMore info
M11-089: Randomized, Double-Blind, Multicenter,Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)